BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 32482114)

  • 1. Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Tang C; Espin-Garcia O; Prica A; Kurkreti V; Kridel R; Keating A; Patriquin CJ; Kuruvilla J; Crump M
    Leuk Lymphoma; 2020 Sep; 61(9):2153-2160. PubMed ID: 32482114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
    Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F
    Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
    Gokmen A; Sahin U; Soydan E; Gokgoz Z; Okcu MK; Ozan U; Arslan O; Ilhan O; Ozcan M
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e885-e892. PubMed ID: 35927182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
    Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
    Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
    Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
    J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma.
    Lisenko K; Cremer M; Schwarzbich MA; Kriegsmann M; Ho AD; Witzens-Harig M; Wuchter P
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1397-1402. PubMed ID: 27060439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
    Crump M; Kuruvilla J; Couban S; MacDonald DA; Kukreti V; Kouroukis CT; Rubinger M; Buckstein R; Imrie KR; Federico M; Di Renzo N; Howson-Jan K; Baetz T; Kaizer L; Voralia M; Olney HJ; Turner AR; Sussman J; Hay AE; Djurfeldt MS; Meyer RM; Chen BE; Shepherd LE
    J Clin Oncol; 2014 Nov; 32(31):3490-6. PubMed ID: 25267740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
    Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L
    Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
    Martínez C; Sureda A; Martino R; Cancelas JA; Madoz P; García J; Brunet S
    Bone Marrow Transplant; 1997 Nov; 20(10):855-8. PubMed ID: 9404926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.
    Zhou P; Liu P; Zhou SY; He XH; Han XH; Qin Y; Yang S; Zhang CG; Gui L; Yao JR; Zhao LY; Zhang SX; Sun Y; Shi YK
    Chin Med J (Engl); 2015 Sep; 128(18):2498-504. PubMed ID: 26365969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
    Kuruvilla J; MacDonald DA; Kouroukis CT; Cheung M; Olney HJ; Turner AR; Anglin P; Seftel M; Ismail WS; Luminari S; Couban S; Baetz T; Meyer RM; Hay AE; Shepherd L; Djurfeldt MS; Alamoudi S; Chen BE; Crump M
    Blood; 2015 Aug; 126(6):733-8. PubMed ID: 26109202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
    Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma].
    Aota Y; Tanaka M; Watanabe N; Tomomatu J; Gotoh A; Komatu N
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):51-5. PubMed ID: 25596679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.
    Kim KH; Joo YD; Sohn CH; Shin HJ; Chung JS; Cho GJ; Shin SH; Kim YS; Lee WS
    Korean J Intern Med; 2009 Mar; 24(1):37-42. PubMed ID: 19270480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
    Gopal AK; Press OW; Shustov AR; Petersdorf SH; Gooley TA; Daniels JT; Garrison MA; Gjerset GF; Lonergan M; Murphy AE; Smith JC; Pagel JM
    Leuk Lymphoma; 2010 Aug; 51(8):1523-9. PubMed ID: 20578815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
    Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
    Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.